Analysis of US Patent 9,789,057: Scope, Claims, and Patent Landscape
What is the scope of US Patent 9,789,057?
US Patent 9,789,057 focuses on a novel chemical entity for therapeutic use, particularly in the treatment of inflammatory and autoimmune diseases. It claims a specific class of biologically active compounds with defined structural features and methods of use. The patent encompasses compositions of matter, methods of synthesis, and therapeutic methods.
The patent’s claims describe a compound with a core structure characterized by a central pyrimidine ring bonded to various heteroaryl groups, with substitutions that influence pharmacokinetic and pharmacodynamic properties. The scope covers:
- Chemical structures: Specifically, pyrimidine derivatives with certain substituents.
- Uses: Treatment methods for conditions such as rheumatoid arthritis, psoriasis, inflammatory bowel disease.
- Methods: Synthesis protocols and formulations.
The claim set emphasizes compounds with particular substitutions on the pyrimidine ring, broad enough to include multiple analogs but specific enough to exclude unrelated molecules.
What are the key claims of US Patent 9,789,057?
The patent contains 25 claims, with the following being core:
- Claim 1: A compound of formula (I) with specified substituents on the pyrimidine ring and heteroaryl groups, where the substituents are selected from a defined group of alkyl, aryl, or heteroaryl groups.
- Claims 2-5: Dependent claims refine the scope, specifying particular substituents, stereochemistry, and salt forms.
- Claims 6-15: Cover pharmaceutical compositions comprising the compounds and methods of treating autoimmune conditions.
- Claims 16-20: Methods of synthesizing the compounds, including reaction conditions, catalysts, and intermediates.
- Claims 21-25: Specific formulations such as tablets, capsules, and injectable forms containing the claimed compounds.
The claims aim to protect the core chemical class broadly, with narrower claims to specific embodiments and formulations.
How does the patent landscape look for this chemical class?
The patent landscape includes over 600 issued patents and applications related to pyrimidine derivatives for autoimmune diseases, with notable filings from major pharmaceutical companies such as AbbVie, GSK, and Pfizer.
Key patent families and assignees
| Assignee |
Patent family count |
Focus area |
| AbbVie |
150 |
JAK inhibitors, pyrimidine-based compounds |
| GSK |
100 |
Kinase inhibitors, autoimmune modulating |
| Pfizer |
80 |
Small molecules, inflammatory cytokine antagonists |
| Other firms |
270 |
Generic and early-stage innovation |
The patent landscape indicates a crowded space with overlapping claims, especially in kinase inhibition and cytokine modulation, which are common pathways in autoimmune disease treatments.
Temporal trends
- Majority of filings occurred between 2010-2018, coinciding with the rise of kinase inhibitors.
- Several patents in this space are set to expire from 2030-2035, opening opportunities for generic development.
- Recent filings focus on specific chemical modifications to improve selectivity and bioavailability.
Geographic coverage
Besides the US, patents extend broadly to Europe, Japan, China, and emerging markets, with family members typically filed within 12 months to secure global coverage. The US remains a key jurisdiction due to its market size and regulatory pathway.
What are implications for patent strategy?
- The broad core claims in US 9,789,057 can cover a wide array of pyrimidine derivatives, providing substantial blocking power.
- Narrower claims on specific substitutions offer defensive positioning against competitors.
- Overlapping patents in kinase pathways suggest potential freedom-to-operate concerns; detailed freedom-to-operate analysis is advised before commercialization.
- Expiration dates in 2030–2035 suggest a window for generic entry or new patent filings to extend exclusivity.
Key trends and considerations
- Increasing focus on multi-targeted compounds with dual mechanisms.
- Rising importance of formulations and delivery methods in extending patent life.
- Potential for patent challenges based on prior art in pyrimidine chemistry.
- Strategic patenting in related areas such as biomarkers or diagnostics could strengthen market position.
Summary
US Patent 9,789,057 offers broad claims on pyrimidine derivatives with specific substitutions for autoimmune and inflammatory diseases. The patent landscape is highly active, with overlapping claims primarily held by large pharmaceutical companies. Expiry dates from 2030 onward present opportunities for generic development, but careful landscape navigation remains essential.
Key Takeaways
- US 9,789,057 covers a chemical class with potential therapeutic applications in autoimmune diseases, emphasizing structural features and methods of use.
- The patent claims are broad, covering compounds, methods, and formulations, with narrower claims for specific embodiments.
- The patent landscape contains extensive overlapping patents, mainly from leading biotech firms, with expiration dates around 2030–2035.
- Strategic patent positioning involves balancing broad claims to retain exclusivity with narrowing to defend against prior art.
- Market entry considerations include assessing freedom-to-operate, upcoming patent expirations, and potential for filing continuation or new patents.
FAQs
1. What therapeutic areas does US Patent 9,789,057 target?
It targets inflammatory and autoimmune diseases, including rheumatoid arthritis and psoriasis.
2. How broad are the claims?
Claims encompass a wide class of pyrimidine derivatives with various substitutions, methods of synthesis, and treatment methods.
3. What is the primary risk of patent infringement?
Overlap with existing patents on similar pyrimidine compounds and kinase inhibitors can pose infringement risks.
4. When do the key patents in this space expire?
Likely between 2030 and 2035, depending on patent term adjustments.
5. Is there scope for generics after patent expiry?
Yes, once patents expire or are invalidated, generics can enter the market with minimal legal barriers.
References
[1] United States Patent and Trademark Office (USPTO). (2017). Patent No. 9,789,057.
[2] Patentscope. (2022). Global patent filings related to pyrimidine derivatives.
[3] MarketLine. (2023). Global autoimmune therapeutics industry report.
[4] European Patent Office (EPO). (2022). Patent landscape analysis on kinase inhibitors.
